non small cell lung cancer
Conditions
Interventions
None listed
Sponsors
Second division, Depertment of Internal Medicine, Hamamatsu University School of Medicine
Department of Respiratory Medicine, Iwata City Hospital Department of Respiratory Medicine, Shizuoka General Hospital Department of Respiratory Medicine, JA Shizuoka Kohseiren Enshu Hospital Department of Respiratory Medicine, Japanese Red Cross Shizuoka Hospital Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital Department of Respiratory Medicine, Shizuoka City Shimizu Hospital Department of Respiratory Medicine, Seirei Mikatahara Hospital Department of Respiratory Med
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients receiving atezolizumab 2. Patients with unresectable or relapsing non-small cell lung cancer 3. Patients who are expected to survive more than 3 months fromthe day of administration. 4. Patients who agreed to participate in this study in writing
Exclusion criteria
Exclusion criteria: 1. Patients with autoimmune diseases or recurrent autoimmune disease 2. Patient with interstitial pneumonia 3. Patients with serious complications 4. Patients with difficult-to-control central nervous lesions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of atezolizumab | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy of atezolizumab | — |
Countries
Japan
Contacts
Public ContactShinpei Kato
Hamamatsu University School of Medicine Second division, Depertment of Internal Medicine
Outcome results
None listed